Literature DB >> 22467055

Advanced glycation end products (AGE) induce the receptor for AGE in the colonic mucosa of azoxymethane-injected Fischer 344 rats fed with a high-linoleic acid and high-glucose diet.

Takasumi Shimomoto1, Yi Luo, Hitoshi Ohmori, Yoshitomo Chihara, Kiyomu Fujii, Tomonori Sasahira, Ayumi Denda, Hiroki Kuniyasu.   

Abstract

BACKGROUND: Advanced glycation end products (AGE) and the receptor for advanced glycation end products (RAGE) are closely associated with colorectal cancer progression. The association between RAGE and AGE in colon carcinogenesis needs to be clarified.
METHODS: Levels of RAGE and AGE were examined in azoxymethane (AOM)-injected Fischer 344 rats fed a control diet (Group C), a 15 % linoleic acid (LA) diet (Group L), a control diet with 10 % glucose drink (Group G), and a 15 % LA diet with 10 % glucose drink (Group L + G). Group L + G showed the most pronounced increase of body weight, blood sugar, and serum insulin.
RESULTS: The rats in Group L + G showed the most pronounced multiplicity of aberrant crypt foci (ACF) and carcinomas with increased mucosal RAGE and AGE. IEC6 rat intestinal epithelial cells treated with AGE showed increased RAGE expression, which was inhibited by treatment with metformin or losartan. In the AOM-injected rat colon cancer model, the levels of RAGE and AGE, and the multiplicity of ACF and carcinomas, in Group L + G rats were suppressed by treatment with metformin or losartan.
CONCLUSIONS: These results suggest that AGE-RAGE induced by high-LA and high-glucose diets substantially enhances colon cancer development; thus, suppression of AGE-RAGE could be a potential target for colon cancer chemoprevention.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22467055     DOI: 10.1007/s00535-012-0572-5

Source DB:  PubMed          Journal:  J Gastroenterol        ISSN: 0944-1174            Impact factor:   7.527


  36 in total

1.  Blockade of RAGE-amphoterin signalling suppresses tumour growth and metastases.

Authors:  A Taguchi; D C Blood; G del Toro; A Canet; D C Lee; W Qu; N Tanji; Y Lu; E Lalla; C Fu; M A Hofmann; T Kislinger; M Ingram; A Lu; H Tanaka; O Hori; S Ogawa; D M Stern; A M Schmidt
Journal:  Nature       Date:  2000-05-18       Impact factor: 49.962

Review 2.  The receptor for advanced glycation end-products has a central role in mediating the effects of advanced glycation end-products on the development of vascular disease in diabetes mellitus.

Authors:  O Hori; S D Yan; S Ogawa; K Kuwabara; M Matsumoto; D Stern; A M Schmidt
Journal:  Nephrol Dial Transplant       Date:  1996       Impact factor: 5.992

3.  Characterization and functional analysis of the promoter of RAGE, the receptor for advanced glycation end products.

Authors:  J Li; A M Schmidt
Journal:  J Biol Chem       Date:  1997-06-27       Impact factor: 5.157

Review 4.  Evolutionary aspects of diet, the omega-6/omega-3 ratio and genetic variation: nutritional implications for chronic diseases.

Authors:  A P Simopoulos
Journal:  Biomed Pharmacother       Date:  2006-08-28       Impact factor: 6.529

5.  The diabetic milieu modulates the advanced glycation end product-receptor complex in the mesangium by inducing or upregulating galectin-3 expression.

Authors:  G Pugliese; F Pricci; G Leto; L Amadio; C Iacobini; G Romeo; L Lenti; P Sale; R Gradini; F T Liu; U Di Mario
Journal:  Diabetes       Date:  2000-07       Impact factor: 9.461

6.  Expression of receptors for advanced glycation end-products (RAGE) is closely associated with the invasive and metastatic activity of gastric cancer.

Authors:  Hiroki Kuniyasu; Naohide Oue; Atsuko Wakikawa; Hideo Shigeishi; Norimasa Matsutani; Kazuya Kuraoka; Reiko Ito; Hiroshi Yokozaki; Wataru Yasui
Journal:  J Pathol       Date:  2002-02       Impact factor: 7.996

Review 7.  Essential fatty acids in health and chronic disease.

Authors:  A P Simopoulos
Journal:  Am J Clin Nutr       Date:  1999-09       Impact factor: 7.045

8.  Association of expression of receptor for advanced glycation end products and invasive activity of oral squamous cell carcinoma.

Authors:  Ujjal K Bhawal; Yoshie Ozaki; Masahiro Nishimura; Masaru Sugiyama; Tomonori Sasahira; Yuji Nomura; Fuyuki Sato; Katsumi Fujimoto; Nobuyuki Sasaki; Masa-Aki Ikeda; Koichiro Tsuji; Hiroki Kuniyasu; Yukio Kato
Journal:  Oncology       Date:  2005-08-26       Impact factor: 2.935

Review 9.  Role of advanced glycation end products (AGEs) and their receptor (RAGE) in the pathogenesis of diabetic microangiopathy.

Authors:  S Yamagishi; M Takeuchi; Y Inagaki; K Nakamura; T Imaizumi
Journal:  Int J Clin Pharmacol Res       Date:  2003

10.  Receptor for advanced glycation end products-binding COOH-terminal motif of amphoterin inhibits invasive migration and metastasis.

Authors:  Henri J Huttunen; Carole Fages; Juha Kuja-Panula; Anne J Ridley; Heikki Rauvala
Journal:  Cancer Res       Date:  2002-08-15       Impact factor: 12.701

View more
  21 in total

Review 1.  The key role of growth hormone-insulin-IGF-1 signaling in aging and cancer.

Authors:  Vladimir N Anisimov; Andrzej Bartke
Journal:  Crit Rev Oncol Hematol       Date:  2013-02-21       Impact factor: 6.312

Review 2.  Do metformin a real anticarcinogen? A critical reappraisal of experimental data.

Authors:  Vladimir N Anisimov
Journal:  Ann Transl Med       Date:  2014-06

Review 3.  Certainty of S100 from Physiology to Pathology.

Authors:  Puneeth Horatti Kuberappa; Bhavana Shivanand Bagalad; Anuradha Ananthaneni; Md Asif Kiresur; Guduru Vijay Srinivas
Journal:  J Clin Diagn Res       Date:  2016-06-01

4.  Metformin inhibits salivary adenocarcinoma growth through cell cycle arrest and apoptosis.

Authors:  Yuqi Guo; Tao Yu; Jian Yang; Tianqing Zhang; Yang Zhou; Fan He; Zoya Kurago; David Myssiorek; Yingjie Wu; Peng Lee; Xin Li
Journal:  Am J Cancer Res       Date:  2015-11-15       Impact factor: 6.166

5.  Plasma concentrations of advanced glycation end-products and colorectal cancer risk in the EPIC study.

Authors:  Elom K Aglago; Casper G Schalkwijk; Heinz Freisling; Veronika Fedirko; David J Hughes; Li Jiao; Christina C Dahm; Anja Olsen; Anne Tjønneland; Verena Katzke; Theron Johnson; Matthias B Schulze; Krasimira Aleksandrova; Giovanna Masala; Sabina Sieri; Vittorio Simeon; Rosario Tumino; Alessandra Macciotta; Bas Bueno-de-Mesquita; Guri Skeie; Inger Torhild Gram; Torkjel Sandanger; Paula Jakszyn; Maria-Jose Sánchez; Pilar Amiano; Sandra M Colorado-Yohar; Aurelio Barricarte Gurrea; Aurora Perez-Cornago; Ana-Lucia Mayén; Elisabete Weiderpass; Marc J Gunter; Alicia K Heath; Mazda Jenab
Journal:  Carcinogenesis       Date:  2021-05-28       Impact factor: 4.944

Review 6.  Impact of Advanced Glycation End products (AGEs) and its receptor (RAGE) on cancer metabolic signaling pathways and its progression.

Authors:  Yadav Sangeeta Muthyalaiah; Bhavana Jonnalagadda; Cordelia Mano John; Sumathy Arockiasamy
Journal:  Glycoconj J       Date:  2022-01-22       Impact factor: 2.916

Review 7.  The Role of Advanced Glycation End-Products in Cancer Disparity.

Authors:  D P Turner
Journal:  Adv Cancer Res       Date:  2016-10-12       Impact factor: 5.767

8.  Role of Glycated High Mobility Group Box-1 in Gastric Cancer.

Authors:  Shingo Kishi; Yukiko Nishiguchi; Kanya Honoki; Shiori Mori; Rina Fujiwara-Tani; Takamitsu Sasaki; Kiyomu Fujii; Isao Kawahara; Kei Goto; Chie Nakashima; Akira Kido; Yasuhito Tanaka; Yi Luo; Hiroki Kuniyasu
Journal:  Int J Mol Sci       Date:  2021-05-13       Impact factor: 5.923

9.  Colorectal polyp model established by transplacental BMP4 RNAi.

Authors:  Xin Jin; Zhongmei Chen; Li Xiang; Qing Luo; Zhenghua Guo; Xionghui Ding; Xianqing Jin
Journal:  Mol Med Rep       Date:  2014-05-07       Impact factor: 2.952

10.  Metformin for cancer and aging prevention: is it a time to make the long story short?

Authors:  Vladimir N Anisimov
Journal:  Oncotarget       Date:  2015-11-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.